These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32985512)

  • 1. Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation.
    Gebri E; Kiss A; Tóth F; Hortobágyi T
    Sci Rep; 2020 Sep; 10(1):15898. PubMed ID: 32985512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation.
    Jasiński M; Maciejewska M; Brodziak A; Górka M; Skwierawska K; Jędrzejczak WW; Tomaszewska A; Basak GW; Snarski E
    Sci Rep; 2021 Nov; 11(1):22507. PubMed ID: 34795377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
    Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
    Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation.
    Abdelhakim H; Shune L; Bhatti S; Cantilena AR; Baran A; Lin TL; Ganguly S; Singh AK; Abhyankar S; Divine C; Lipe B; McGuirk J; Allin D; Aljitawi OS
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1713-1719. PubMed ID: 31170519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation.
    Bolwell BJ; Kalaycio M; Sobecks R; Andresen S; Kuczkowski E; Bernhard L; Lomax R; Kohuth J; Mendiola S; Rybicki L; Pohlman B
    Bone Marrow Transplant; 2002 Nov; 30(9):587-91. PubMed ID: 12407433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
    Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial.
    Raoufinejad K; Shamshiri AR; Pezeshki S; Chahardouli B; Hadjibabaie M; Jahangard-Rafsanjani Z; Gholami K; Rajabi M; Vaezi M
    Daru; 2019 Dec; 27(2):709-720. PubMed ID: 31713184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing the incidence and severity of oral mucositis in patients undergoing autologous stem cell transplantation.
    Salvador PT
    Can Oncol Nurs J; 2005; 15(1):29-34. PubMed ID: 15779780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation.
    Sakellari I; Angelopoulou M; Tsopra O; Dervenoulas I; Tsirigotis P; Spyridonidis A; Liga M; Tsionos K; Anargyrou K; Pouli A; Anagnostopoulos A
    Ann Hematol; 2015 Oct; 94(10):1733-40. PubMed ID: 26141369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oral management on the severity of oral mucositis during hematopoietic SCT.
    Yamagata K; Arai C; Sasaki H; Takeuchi Y; Onizawa K; Yanagawa T; Ishibashi N; Karube R; Shinozuka K; Hasegawa Y; Chiba S; Bukawa H
    Bone Marrow Transplant; 2012 May; 47(5):725-30. PubMed ID: 21874059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary antioxidant enzymes associated with oral toxicity in haematopoietic cell transplantation: An observational study.
    Bezinelli LM; Eduardo FP; Ferreira MH; Gobbi M; Lopes RMG; Rosin FCP; Vogel C; Hamerschlak N; Corrêa L
    Eur J Clin Invest; 2021 Feb; 51(2):e13379. PubMed ID: 32959899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early salivary changes in multiple myeloma patients undergoing autologous HSCT.
    van Leeuwen S; Proctor GB; Potting C; Ten Hoopen S; van Groningen L; Bronkhorst EM; Blijlevens N; Huysmans M
    Oral Dis; 2018 Sep; 24(6):972-982. PubMed ID: 29637662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
    Villela L; Sureda A; Canals C; Sanz MA; Martino R; Valcárcel D; Altés A; Briones J; Gómez M; Brunet S; Sierra J
    Haematologica; 2003 Mar; 88(3):300-5. PubMed ID: 12651269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
    Fernandez HF; Tran HT; Albrecht F; Lennon S; Caldera H; Goodman MS
    Biol Blood Marrow Transplant; 2002; 8(9):486-92. PubMed ID: 12374453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.
    Strobel ES; Bauchmüller K; Ihorst G; Engelhardt M
    Leuk Lymphoma; 2007 Nov; 48(11):2255-60. PubMed ID: 17990184
    [No Abstract]   [Full Text] [Related]  

  • 18. The salivary proteome in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients: a labelled and label-free proteomics approach.
    van Leeuwen SJM; Proctor GB; Staes A; Laheij AMGA; Potting CMJ; Brennan MT; von Bültzingslöwen I; Rozema FR; Hazenberg MD; Blijlevens NMA; Raber-Durlacher JE; Huysmans MCDNJM
    BMC Oral Health; 2023 Jul; 23(1):460. PubMed ID: 37420206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photobiomodulation: a promising innovative approach for preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation.
    Stocker N; Baltes V; Bellaiche S; Brouillard F; Belmoufid N; Rousseau C; Bonnin A; Van de Wyngaert Z; Ricard L; Banet A; Malard F; Duléry R; Mohty M; Brissot E
    Support Care Cancer; 2022 Oct; 30(10):8211-8216. PubMed ID: 35810217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation.
    Shouval R; Kouniavski E; Fein J; Danylesko I; Shem-Tov N; Geva M; Yerushalmi R; Shimoni A; Nagler A
    Eur J Haematol; 2019 Oct; 103(4):402-409. PubMed ID: 31332836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.